Key Takeaways
- A sell-side advisor represents the practice owner through valuation, marketing, bidding, negotiation, and closing. This choice can be one of the main factors in final proceeds and deal success.
- Owners of premier practices ($1M+ revenue) should clarify personal goals and timing first, because doctor-to-doctor sales and DSO affiliations involve different post-close commitments and valuation methods.
- A CPA-led, buyer-ready EBITDA valuation before going to market can protect value. Every accepted or rejected add-back can change purchase price by a multiple of its dollar amount.
- A structured, competitive bid process with vetted buyers and clear deadlines can create tension that improves price and terms and reduces re-trading risk.
- McLerran & Associates runs a dual-path, CPA-led process with an 85–90% close rate. Schedule a free, confidential discovery call to see how the right representation can help protect your value, staff, and legacy.
Core Terms Every Selling Dentist Should Know
This guide uses several financial and deal terms that appear in nearly every dental transition conversation. A shared vocabulary keeps discussions clear.
- EBITDA – Earnings Before Interest, Taxes, Depreciation, and Amortization. In plain terms, this is the cash profit a practice generates before financing costs and non-cash accounting charges. Institutional buyers, including private-equity-backed Dental Service Organizations (DSOs), often base offers on a multiple of this number after adjusting it for owner-specific expenses.
- Adjusted EBITDA – EBITDA restated to show true, recurring profitability. The calculation adds back owner compensation above a market associate wage, personal expenses run through the practice, and one-time non-recurring costs. Most significant buyers in the dental market base offers on a multiple of Adjusted EBITDA, so accuracy here can be one of the main foundations of the entire transaction.
- Valuation – The process of estimating what a practice may be worth to a specific type of buyer. Doctor-to-doctor valuations are commonly expressed as a percentage of annual collections. DSO valuations are usually expressed as a multiple of Adjusted EBITDA.
- LOI (Letter of Intent) – A non-binding document where a buyer states the proposed price, structure, and key terms before formal due diligence begins. The LOI sets expectations but does not lock every detail. Earnings definitions, earnout terms, and deal structure often remain open for negotiation.
- Due diligence – The buyer’s formal review of the practice’s financials, operations, legal standing, and clinical data after the LOI is signed. Weak or poorly documented valuations can be most vulnerable at this stage.
- DSO (Dental Service Organization) – A company that acquires or affiliates with dental practices and provides non-clinical business support such as HR, billing, marketing, and compliance. The dentist usually continues practicing clinically.
- Private buyer – An individual dentist who purchases a practice outright, usually with an SBA or conventional dental loan.
- Earnout – A portion of the purchase price paid after closing if the practice meets agreed performance targets. Earnouts shift some post-close risk to the seller.
- Equity rollover – A portion of sale proceeds paid as ownership shares in the acquiring DSO or its parent company instead of cash. Up to about 40% of a DSO deal can be structured as equity rollover, so the buyer’s financial health can become a significant concern for the seller.
- Recapitalization (recap) – A future event where the DSO’s private equity sponsor sells or refinances the platform. Equity holders, including dentists who rolled equity, may receive a “second bite of the apple” if the recap is successful.
This guide focuses on owners of premier practices generating $1 million or more in annual revenue who are 1 to 5 years from an intended exit and are comparing a doctor-to-doctor sale with a DSO or private equity affiliation.
Step 1: Define Your Goals and Exit Timing
Clear personal goals give structure to every later decision. Many owners start by saying they want to “maximize price,” then realize they also care about continuing clinical work, protecting long-tenured staff, or preserving a specific clinical philosophy.
Timeline can be just as influential. Five to 10 years before the intended close can be a high-leverage window for exit planning, with about 5 years often emerging as the key horizon for value-driving actions such as EBITDA normalization. Decisions on corporate structure, associate hiring, and financial reporting quality in years 5 through 3 can have a large impact on sale price and available pathways.
Owners closer to exit have less time to reshape numbers but can still benefit from a structured, competitive process. The two main paths also carry different post-close commitments, which tie directly into timing preferences.
A doctor-to-doctor walk-away sale usually involves a transition period of roughly 4 to 8 weeks, then the seller can retire or move on. DSO transactions commonly require the selling dentist to remain for at least 5 years after closing, which creates a longer-term professional commitment. Owners who want a near-term clean exit may find the private-buyer path more compatible, while those who want to keep practicing while reducing management burden may find a DSO affiliation more suitable.
Step 2: Compare Doctor-to-Doctor Sales and DSO Affiliations
The dental transition market largely splits between two buyer types. Each path uses different valuation methods, deal structures, and post-close expectations.
Doctor-to-doctor (private buyer) sales involve an individual dentist, usually financed through an SBA 7(a) or conventional dental loan. For practices above $1 million in net revenue, prices often clear at a percentage of net revenue, which is shaped by what a single buyer can finance. The buyer steps into the owner role and runs the practice directly, which can support clinical culture and staff continuity. Closing timelines are often shorter than DSO deals.
DSO and private equity affiliations are institutional acquisitions. The buyer acquires the practice’s revenue stream and folds it into a larger platform. Institutional buyers typically normalize EBITDA by replacing the owner’s pay with a market-rate associate salary, then apply a multiple to that adjusted figure. Practices with $1 million to $3 million in revenue can qualify for EBITDA-based valuations that may exceed what a private buyer can pay. The headline number, however, can differ from net-to-seller proceeds once earnouts, equity rollover, taxes, and post-close commitments are considered.
The better path can depend on practice size, profitability, post-close plans, and risk tolerance. Owners in the $1.5 million to $3 million revenue range can often qualify for either path, so a side-by-side comparison built on sound valuation work becomes especially useful. That comparison is only as reliable as the valuation behind it, which makes the next step a natural focus.
Step 3: Insist on a CPA-Led EBITDA Valuation That Holds Up
Valuation quality can quietly shape the entire outcome. A number set by the buyer, or produced by a quick free estimate, often becomes the anchor for what the owner ultimately receives. If that number cannot withstand scrutiny, it may be challenged during due diligence and the deal can be re-traded downward.
In a 7-times EBITDA transaction, a $50,000 difference in adjusted EBITDA can produce a $350,000 difference in purchase price. Each add-back can therefore matter far more than its face value. A CPA-led valuation breaks out every add-back, such as above-market owner compensation, personal expenses, and one-time costs, and documents each item so it can stand up to a buyer’s quality-of-earnings review.
Practices with clean books and well-documented, defensible EBITDA adjustments are more likely to protect their multiples, while practices where add-backs collapse during diligence often experience mid-process price cuts. An advisor should deliver institutional-quality work before the practice goes to market, not a rough estimate that gets revised once buyers start asking detailed questions.
When you evaluate an advisor’s valuation quality, ask specific questions. Is a CPA preparing or directly overseeing the analysis? This can help align the work with institutional standards. Does the valuation include documentation for every add-back, with clear support? Strong documentation can reduce the risk of re-trading during diligence. Has the firm’s methodology been tested in prior deals under buyer scrutiny? A valuation that has never faced real buyer review remains theoretical. Finally, does the advisor stand behind the number through closing? A firm that will not defend its own work may not fully trust it.
Step 4: Build a Competitive Bid Process With Real Buyer Tension
A single offer, even if it looks generous, does not reflect a true market. Without competition, the buyer often sets both price and terms, and the seller has limited leverage.
Unsolicited single-buyer offers can underprice dental practices compared with marketed processes that include a prospectus and at least 3 qualified bidders. Competition among credible buyers can lift value and also improve cash at close, reduce earnout exposure, limit rollover requirements, and balance employment terms. It can also lower the risk of aggressive late-stage re-trading.
A structured auction-style process can turn a strong valuation into a strong outcome. This type of process usually reaches out to a vetted pool of buyers, sets clear deadlines for best-and-final bids, and maintains confidentiality throughout.
An advisor should explain how many buyers they typically approach, how they qualify those buyers before inviting offers, and what their usual offer count looks like. Vague answers on these points can be a warning sign.
Schedule a free, confidential discovery call with McLerran & Associates to see how a competitive bid process can be tailored to your practice and goals.
Step 5: Screen Buyers Carefully and Avoid Weak Platforms
The highest headline price does not always create the best long-term result. In DSO transactions, equity rollover portions are illiquid and depend on the DSO platform achieving a successful future exit. Partnering with an undercapitalized or poorly managed DSO can put a meaningful share of proceeds at risk.
A qualified sell-side advisor can vet buyers the way an investor reviews a stock. This review can include the DSO’s profitability, revenue growth at existing locations, management team experience, and the track record of its private equity sponsor. Buyers with a history of poor post-close environments, broken promises to staff, disruptive operational changes, or financial instability can be screened out before they reach the table.
For private-buyer deals, vetting usually focuses on financing strength, lender approval, down payment size, and the buyer’s clinical philosophy and culture fit. A buyer offering a slightly lower price may still present less risk if the financing is stronger and fewer conditions must be met before closing.
Step 6: Compare Real After-Tax Cash Across Deal Structures
DSO deal structures can be complex, so modeling can be more reliable than intuition. A typical offer may include cash at close, equity rollover at the joint-venture or holding-company level, and an earnout tied to production after closing.
The difference between a well-structured sale and a poorly structured one can represent a meaningful percentage of net-to-seller proceeds. Asset versus stock treatment, tax elections, and state residency can all affect after-tax results.
Joint-venture equity often distributes income annually, which can provide a more predictable floor but a lower ceiling. Holding-company equity usually does not distribute income but can increase in value at a future recapitalization, which introduces more risk and potential reward. Many DSOs expect a recapitalization within 12 to 36 months, and that timing can influence how much equity rollover feels appropriate.
An advisor can add value by producing multi-year, multi-structure financial forecasts. These models can show what each path might net the owner over 3, 5, 7, and 10 years, using conservative recap assumptions. This approach allows an apples-to-apples comparison instead of relying on a single headline number.
Step 7: Use Close Rates and Valuation Lift to Judge Advisors
An advisor’s track record can be one of the clearest signals of process quality. Two metrics can be especially helpful: the percentage of engagements that close and the improvement in sale price compared with what owners might have achieved without specialist representation.
Sellers without specialist support often sit across from advised, commercially experienced buyers. That imbalance can show up in lower prices, weaker terms, and more failed deals. McLerran & Associates reports a transaction completion rate of about 85 to 90%, compared with an industry norm closer to 35 to 40% and do-it-yourself close rates that can run as low as 15 to 20%.
When you interview advisors, ask for close-rate data, average offer counts, and examples of valuation outcomes relative to initial expectations. Advisors who cannot provide specific answers may be revealing limits in their process.
Schedule a free, confidential discovery call with McLerran & Associates and ask directly about transaction rates, valuation results, and how the firm’s dual-path process has performed for practices similar to yours.
Advisor Types Explained Without a Comparison Table
Different advisor types bring different strengths and limits, and these differences can be easier to understand in plain language than in a grid.
DIY / For-Sale-By-Owner approaches usually involve one buyer, no formal valuation, and limited competitive tension. The buyer often sets the price, and close rates can be relatively low.
Local generalist brokers may know the local market but often focus on one sale path and may not specialize in dental or institutional buyers. Valuation work and buyer pools can be limited.
Multi-vertical advisors work across several healthcare or professional fields. They may bring broader capital markets experience but can lack deep dental-specific insight or relationships.
Free-valuation firms often provide quick estimates as a lead-generation tool. These valuations may not meet institutional standards, which can increase the risk of re-trading later.
Dental-focused sell-side advisors such as McLerran & Associates concentrate on dental practices nationwide, run both private-buyer and DSO processes, and build deals on CPA-led, buyer-ready valuations. These firms typically maintain vetted buyer lists, screen out weak platforms, and report higher close rates across many completed transactions.
Common Transition Challenges and How to Prevent Them
Even well-prepared transitions can encounter friction. Several patterns appear frequently, and many can be reduced with early planning.
Valuation gaps between expectations and offers. This gap often reflects a valuation that did not meet institutional standards or an inflated free estimate used as marketing. Prevention can include commissioning a CPA-led, buyer-ready valuation before going to market and locking the EBITDA definition into the LOI.
Incomplete or disorganized financials. Seller preparation usually requires 3 years of profit and loss statements, 3 years of business tax returns, a current year-to-date P&L, and the doctor’s W-2s and owner distributions. Missing or inconsistent records give buyers room to challenge EBITDA and reduce offers. Starting financial organization 2 to 3 years before a sale can help.
Buyer-fit concerns surfacing late. A buyer who initially appears aligned on clinical philosophy or staff commitments may reveal conflicts during diligence or negotiation. Thorough vetting before the LOI stage and reference checks with previously acquired practices can reduce this risk.
Post-LOI re-trading. Some buyers agree to a price at LOI, then seek reductions during diligence by questioning EBITDA or operations. Embedding the EBITDA definition and the seller’s add-back schedule directly into the LOI can limit valuation renegotiation when seller leverage has decreased. Strong preparation and an advisor who defends the numbers through closing can also help.
Confidentiality breaches. Staff or patients learning about a pending sale too early can damage goodwill, accelerate departures, and reduce value. Prevention often includes confidentiality agreements with all prospective buyers and careful control of information flow by the advisor.
How to Measure a Successful Dental Practice Transition
Several objective indicators can help owners judge whether a transition met expectations, both before and after closing.
- Valuation defensibility: The agreed price at LOI holds through due diligence without material re-trading, which suggests the EBITDA analysis met institutional standards.
- Buyer interest: The process generates multiple qualified offers, showing that the practice reached a broad and relevant buyer pool.
- Timeline adherence: The transaction closes within the expected window, without major delays from avoidable diligence issues or missing documents.
- Staff retention: Key clinical and administrative team members stay through and after the transition, preserving the goodwill that supports the practice’s value.
- After-tax net proceeds: The owner’s actual cash received, after taxes, fees, and structure, aligns reasonably with the multi-year financial model prepared before signing the LOI.
Frequently Asked Questions
How far in advance should I start working with a sell-side advisor?
A 3 to 5 year runway before your intended exit can be helpful. That timeframe allows room to improve financial documentation, reduce dependence on the owner’s personal production, and strengthen profitability, which can all support a higher sale price. Owners closer to exit can still benefit from a structured, competitive process, even with less time.
McLerran & Associates also updates a valuation for free one year after the initial analysis if you are not yet ready to transact, so getting educated early does not require a commitment to sell immediately.
What inputs go into a dental practice EBITDA valuation?
A CPA-led EBITDA valuation usually starts with net income, then adds back interest, taxes, depreciation, and amortization to reach a base EBITDA figure. The advisor then adjusts for owner-specific items such as compensation above a market associate wage, personal expenses run through the practice, and one-time non-recurring costs like emergency equipment replacement.
Each add-back benefits from documentation that explains the nature of the expense, the annual amount, and why it is non-recurring or owner-specific. The resulting Adjusted EBITDA is then multiplied by a market-appropriate multiple to estimate value. The quality of this normalization and documentation can be one of the main factors in whether the valuation holds up during buyer due diligence.
How do DSO deal structures differ from private-buyer deals, and which is better?
Private-buyer transactions typically pay the full agreed price in cash at closing, with no performance contingencies, and require only a short transition period. DSO transactions often pay 60 to 80% of the consideration in cash at close, with the balance in equity rollover and, in many cases, an earnout tied to post-close production.
DSO headline multiples can be higher than what a private buyer can finance, but after-tax, after-risk net-to-seller proceeds depend on the DSO’s quality, equity structure, and earnout terms. Neither path fits every situation. The better choice can depend on practice size, profitability, post-close plans, and risk tolerance.
McLerran & Associates prepares side-by-side valuations that quantify potential outcomes in both markets, which can help owners compare options on a consistent basis.
When should I delay a sale rather than proceed?
Delay can make sense when financials are disorganized, EBITDA margins fall below levels that attract strong institutional interest, the owner remains heavily tied to production without associate support, or a specific operational issue such as payer mix, equipment condition, or lease terms would materially reduce buyer interest.
In these situations, 12 to 36 months of targeted improvement can sometimes produce a better outcome than selling immediately. McLerran & Associates can provide a candid assessment of current readiness and timing, rather than encouraging a sale that may not serve the owner’s long-term interests.
What makes McLerran & Associates different from other dental transition advisors?
McLerran & Associates focuses on dental sell-side advisory work and runs both doctor-to-doctor and DSO pathways in roughly equal measure, which can give owners a more complete comparison than single-lane brokers. Each engagement starts with a CPA-led, buyer-ready EBITDA valuation completed before going to market, so the numbers are prepared for buyer review.
The firm runs a structured, auction-style competitive bid process among a vetted pool of buyers and screens out poorly performing DSOs before they reach the table. Across a large number of completed sales over many years, McLerran & Associates reports a transaction completion rate of about 85 to 90%, compared with an industry norm closer to 35 to 40%.
Ready to Talk About Your Transition?
Choosing a dental sell-side advisor can be one of the most consequential decisions in a practice owner’s financial life. The advisor’s process can influence how much value you keep, how your staff experiences the change, and how your clinical legacy continues.
A dual-path advisor with CPA-led valuations, a competitive bid process, and a documented record of closing transactions can provide a strong baseline of support for premier practice owners.
McLerran & Associates has guided owners of premier dental practices through both main transition pathways for roughly 35 years, with offices in Cleveland, Atlanta, Northern Virginia, Los Angeles, and Phoenix serving clients nationwide. The firm focuses on selling practices, not just listing them.
Schedule a free, confidential discovery call with McLerran & Associates to discuss your practice, your timing, and how a dual-path, CPA-led transition process could affect your outcome. You can also reach the team at (512) 900-7989 or info@dentaltransitions.com.
